Literature DB >> 19132792

Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.

Silje W Syversen1, Guro L Goll, Désirée van der Heijde, Robert Landewé, Per Ivar Gaarder, Sigrid Odegård, Espen A Haavardsholm, Tore K Kvien.   

Abstract

OBJECTIVE: As current predictors of joint destruction have low specificity, serological biomarkers reflecting bone and cartilage destruction have been proposed as tools in assessing prognosis of rheumatoid arthritis (RA). We examined whether serum concentrations of a panel of biomarkers could predict radiographic progression in patients with RA.
METHODS: A cohort of 238 patients with RA was followed longitudinally for 10 years with collection of clinical data and serum samples. These analyses focus on the 136 patients with radiographs of the hands available at baseline and at 5 and/or 10 years. Radiographs were scored according to the van der Heijde-modified Sharp score (SHS). Baseline sera were analyzed for receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), human cartilage glycoprotein-39 (YKL-40), C2C, collagen cross-linked C-telopeptide (CTX-I), and cartilage oligomeric matrix protein (COMP). Multivariate linear and logistic regression analyses were used to identify predictors of radiographic progression.
RESULTS: Baseline CTX-I levels were higher in progressors [0.41 ng/ml (interquartile range 0.31-0.75)] than in nonprogressors [0.32 ng/ml (IQR 0.21-0.49)], and were independently associated with 10-year change in radiographic damage score [ss = 16.4 (IQR 5.7-27.1)]. We found no association between radiographic progression and baseline serum levels of RANKL, OPG, C2C, YKL-40, or COMP.
CONCLUSION: This longterm followup study of patients with RA indicates a relationship between elevated CTX-I levels in serum and subsequent joint destruction. This association was, however, weak, and our study does not support that serum CTX-I or any of the other tested biomarkers will serve as more useful prognostic markers than current predictors such as anti-cyclic citrullinated peptide, radiographic damage early in the disease course, and signs of inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132792     DOI: 10.3899/jrheum.080180

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

2.  Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease.

Authors:  Shu-Hsin Lee; Ching-Yi Lin; Po-Hui Wang; Chih-Ping Han; Shun-Fa Yang; Jinghua Tsai Chang; Meng-Chih Lee; Long-Yau Lin; Maw-Sheng Lee
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

3.  Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria.

Authors:  F Genovese; A S Siebuhr; K Musa; J A Gallagher; A M Milan; M A Karsdal; J Rovensky; A C Bay-Jensen; L R Ranganath
Journal:  JIMD Rep       Date:  2015-03-19

4.  Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.

Authors:  K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa
Journal:  Osteoporos Int       Date:  2018-03-24       Impact factor: 4.507

5.  Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis.

Authors:  A O El Defrawy; T A Gheita; H M Raslan; M M El Ansary; A H El Awar
Journal:  Z Rheumatol       Date:  2016-11       Impact factor: 1.372

6.  Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study.

Authors:  S Louis Bridges; Zenoria L Causey; Paula I Burgos; B Quynh N Huynh; Laura B Hughes; Maria I Danila; Amalia van Everdingen; Stephanie Ledbetter; Doyt L Conn; Ashutosh Tamhane; Andrew O Westfall; Beth L Jonas; Leigh F Callahan; Edwin A Smith; Richard Brasington; Larry W Moreland; Graciela S Alarcón; Désirée M van der Heijde
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

Review 7.  The role of biomarkers in the management of patients with rheumatoid arthritis.

Authors:  Jackie Nam; Edith Villeneuve; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

Review 8.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

9.  Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy.

Authors:  Fangze Zhang; Rui Ding; Ping Li; Cuili Ma; Ding Song; Xuetong Wang; Tianjiao Ma; Liqi Bi
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity.

Authors:  Rajalingham Sakthiswary; Shamala Rajalingam; Heselynn Hussein; Radhika Sridharan; Abdul Wahab Asrul
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.